GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Stemcells, Inc. (STEM) [hlAlert]

Rating:
Buy STEM
down 75.77 %

Stemcells, Inc. (STEM) rated Buy with price target $2.50 by Maxim Group

Posted on: Thursday,  Aug 23, 2012  10:25 AM ET by Maxim Group

Maxim Group rated Buy Stemcells, Inc. (NASDAQ: STEM) on 08/23/2012, when the stock price was $1.61. Since
then, Stemcells, Inc. has lost 75.78% as of 11/24/2015's recent price of $0.39.
If you would have followed this Maxim Group's recommendation on STEM, you would have lost 75.77% of your investment in 1188 days.

StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/23/2012 10:25 AM Buy
None
1.61 2.50
as of 12/31/2012
1 Week up  3.16 %
1 Month down  -9.44 %
3 Months down  -20.87 %
1 YTD up  1.24 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy